The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...

With an expanded recommendation from the Center for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization ...

Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.

On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for ...

An agency panel recommended lowering the age for routine vaccination from 65 to 50, boosting the revenue outlook for multiple ...

Barely three years ago, Pfizer was the toast of the pharmaceutical world and Bourla, who was elevated to the top job in 2019, wrote a book about the race to develop the coronavirus vaccine.

Albert Bourla, who four years ago led Pfizer through its scientific and financial triumph during the COVID-19 pandemic, is ...

Pfizer Inc. (PFE) announced that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization ...

The company also has promising candidates in immunology, rare diseases, and vaccines. This diverse pipeline provides multiple opportunities for future growth. Pfizer faces near-term challenges as ...

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating on October 21. David Risinger ...

LONDON, Sept 25 (Reuters) - Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday gave Pfizer permission to take the case to the ...

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pfizer has earned a nod from the U.S. regulator for another of its products in the indication. On Friday, the FDA signed ...